Rigel Pharmaceutical Inc. Registered Shares DL -,001
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
403.08%
Market Cap
-
P/E Ratio
2.20
Dividend Yield
0.00 %
Earnings per Share
17.27 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 7.345 G | 0 Units |
| PRICE DETERMINATION TIME | 06/26/2024 / 07:15:07 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 7.67 | 7.345 |
| PREV. DAY'S PRICE | 7.725 | (06/25) |
| CHANGE DAY BEFORE | -0.38 | -4.92 % |
| 52 WEEK HIGH / LOW | 76.7 (06/26) | 6.678 (10/25) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -1.33 | 0.91 | 17.27 | 2.97 | 2.97 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | 17.01 | 2.20 | 11.92 | 11.92 |
PRICE - BOOK RATIO | - | 90.60 | 2.00 | - | - |
PRICE - SALES RATIO | 2.16 | 1.66 | 2.74 | - | - |
PRICE - CASH FLOW RATIO | - | 9.45 | 10.67 | - | - |
Master Data
| WKN | A40EFY |
| ISIN | US7665597024 |
| SYMBOL | RI2A |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | RIGEL PHARMACEUT. DL-,001 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 08:00:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 791.38 % | 801.23 % | 462.62 % | 554.93 % | 403.08 % | 96.71 % | 253.13 % | 432.63 % |
| HIGH | 76.70 | 76.70 | 76.70 | 76.70 | 76.70 | 76.70 | 76.70 | 76.70 |
| LOW | 7.73 | 7.73 | 7.73 | 7.73 | 6.68 | 6.24 | 6.24 | 7.73 |
Dividende
pro Aktie
RIGEL PHARMACEUT. DL-,001 does not deliver dividend information
Company profile
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.